Consensus Chemed Corporation

Stocks

CHE

US16359R1032

Healthcare Facilities & Services

Market Closed - NYSE 00:00:02 06/11/2026 +03			5-day change	1st Jan Change
533.77 ^USD	-2.71%		-1.50%	+24.75%

11:47pm	Chemed Insider Sold Shares Worth $1,075,800, According to a Recent SEC Filing	MT
11-03	Chemed Insider Sold Shares Worth $494,196, According to a Recent SEC Filing	MT

Evolution of the Average Target: Chemed Corporation

Evolution of the Target Price: Chemed Corporation

Changes in Analyst Recommendations: Chemed Corporation

2855774244a7ad7bf140163792.mRwDyUGX_QPPjfjlUaB7IqtjFuPpwz3jlGfyk3r_Xog.10Zphib1smDiuLOmPs43b8UrVNuNhgyb8leb1BOYa_nQX1S8KOOXNaC-lw~014933baacbfaf67b7a6822448b550a8

Analysts' recommendations: Chemed Corporation

10-29	UBS Adjusts Price Target on Chemed to $675 From $650, Keeps Buy Rating	MT
10-29	Oppenheimer Adjusts Price Target on Chemed to $625 From $590, Maintains Outperform Rating	MT
10-29	RBC Raises Price Target on Chemed to $585 From $548, Keeps Sector Perform Rating	MT
10-28	Chemed Q3 Beat, Guidance Raise Reflect Vitas Strength, BofA Says	MT
10-28	BofA Adjusts Price Target on Chemed to $555 From $550, Keeps Neutral Rating	MT
10-28	BofA Adjusts Price Target on Chemed to $555 From $550, Keeps Buy Rating	MT
10-28	Jefferies Upgrades Chemed to Buy From Hold, Price Target is $620	MT
10-28	Analyst recommendations: Boeing, Qiagen, Spotify, Applovin, Fedex…
09-25	UBS Initiates Chemed at Buy With $650 Price Target	MT
07-31	Oppenheimer Adjusts Price Target on Chemed to $590 From $500, Maintains Outperform Rating	MT
07-30	RBC Raises Price Target on Chemed to $548 From $436, Keeps Sector Perform Rating	MT
07-30	The Fed Gets a Better Inflation Number
07-30	Analysts recommendations: Humana, Lam Research, Procter & Gamble, Carvana, Fair Isaac…
04-27	Chemed' VITAS Continues to Build Momentum, RBC Says	MT
04-27	RBC Lifts Price Target on Chemed to $436 From $422, Keeps Sector Perform Rating	MT
03-31	Chemed Can Unlock Value From Roto-Rooter Unit, Oppenheimer Says	MT
02-27	Chemed's Roto-Rooter Unit Faces Cost Pressures as Hospice Segment Looks Bullish, RBC Says	MT
02-27	Oppenheimer Adjusts Price Target on Chemed to $500 From $580, Maintains Outperform Rating	MT
02-27	RBC Downgrades Chemed to Sector Perform From Outperform, Cuts Price Target to $422 From $572	MT
01-22	Jefferies Downgrades Chemed to Hold From Buy, Adjusts Price Target to $475 From $550	MT
01-22	Analyst recommendations: Datadog, Albemarle, Halliburton, Netflix…
11-10	RBC Lowers Price Target on Chemed to $572 From $589, Keeps Outperform Rating	MT
11-04	Analysts recommendations: Apple, Comcast, Crocs, Eli Lilly, Palantir…
02/09/25	Analysts recommendations: Acuity, Block, Elf Beauty, Fortinet, Nvidia…
02/09/25	Jefferies Upgrades Chemed to Buy From Hold, Adjusts Price Target to $550 From $490	MT

More recommendations

Other Healthcare Facilities & Services

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CHEMED CORPORATION					+12.46%
	CVS HEALTH CORPORATION					+44.47%
	HCA HEALTHCARE, INC.					-6.9%
	NATERA, INC.					+6.48%
	FRESENIUS SE & CO. KGAA					+9.78%
	LABCORP HOLDINGS INC.					+3.93%
	QUEST DIAGNOSTICS INCORPORATED					+0.62%
	TENET HEALTHCARE CORPORATION					+4.07%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+24.49%
	IHH HEALTHCARE					+32.77%
	Average					+13.22%
	Weighted average by Cap.					+13.84%